Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
breyanzi sospensione
bristol-myers squibb sa - lisocabtagenum maraleucelum , enthält genetisch modifizierte zellen (cd4+ oder cd8+ komponente, zieldosis 100x10e6 car+ t-zellen in zielverhältnis 1:1 von cd4+ und cd8+ komponenten) - sospensione - suspension: lisocabtagenum maraleucelum , enthält genetisch modifizierte zellen (cd4+ oder cd8+ komponente, zieldosis 100x10e6 car+ t-zellen in zielverhältnis 1:1 von cd4+ und cd8+ komponenten) 5.5 bis 322x10e6 car+ t-zellen, cryostor cs10, dextranum 40, dimethylis sulfoxidum, natrii chloridum, natrii gluconas, natrii acetas trihydricus, kalii chloridum, magnesii chloridum hexahydricum, aqua ad iniectabile, albumini humani solutio, n-acetyltryptophanum natricum, acidum caprylicum, ad praeparationem pro. - breyanzi ist indiziert zur behandlung von erwachsenen patienten mit diffusem grosszelligem b-zell-lymphom (dlbcl), high-grade-b-zell lymphom (hgbcl) oder primär mediastinalem grosszelligem b-zell-lymphom (pmbcl), das auf die erstlinien-chemoimmuntherapie refraktär ist oder innerhalb von 12 monaten nach der erstlinien-chemoimmuntherapie rezidiviert • rezidiviertem oder refraktärem (r/r) dlbcl, hgbcl oder pmbcl nach zwei oder mehr systemischen therapielinien. - trapianto: gentherapieprodukt
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
abecma infusionsdispersion von 260 bis 500 × 10e6 car-positiven lebensfähigen t-zellen
bristol-myers squibb sa - idecabtagenum vicleucelum 260-500 x 10⁶ car-positive viable t zellen - von 260 bis 500 × 10e6 car-positiven lebensfähigen t-zellen - beutel 260 bis 500 × 10e6 car-positiven lebensfähigen t-zellen: idecabtagenum vicleucelum 260-500 x 10⁶ car-positive viable t zellen, natrii chloridum, natrii gluconas, natrii acetas trihydricus, kalii chloridum, magnesii chloridum 4.5-hydricum, aqua ad iniectabile, cryostor cs10, ad praeparationem pro. - abecma ist für die behandlung von erwachsenen patienten mit rezidiviertem und refraktärem multiplem myelom indiziert, die zuvor mindestens drei therapien erhalten haben, inklusive einem immunmodulatorischen wirkstoff, einem proteasom-inhibitor und einem anti-cd38-antikörper, und welche eine progredienz zur letzten therapie gezeigt haben. - trapianto: gentherapieprodukt
Unione Europea -
italiano -
EMA (European Medicines Agency)
humira
abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - immunosoppressori - si prega di fare riferimento al documento informativo del prodotto.
Unione Europea -
italiano -
EMA (European Medicines Agency)
tyenne
fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosoppressori - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.
Italia -
italiano -
AIFA (Agenzia Italiana del Farmaco)
idalman
i.b.n. savio s.r.l - olmesartan medoxomil - olmesartan medoxomil
Unione Europea -
italiano -
EMA (European Medicines Agency)
lunsumio
roche registration gmbh - mosunetuzumab - linfoma, follicolare - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
tecvayli 30 mg/3 ml soluzione iniettabile
janssen-cilag ag - teclistamabum - soluzione iniettabile - teclistamabum 30 mg, natrii acetas trihydricus, acidum aceticum glaciale, saccharum, polysorbatum 20, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 3 ml corresp. natrium 0.75 mg. - multipli myelom - biotechnologika
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
tecvayli 153 mg/1.7 ml soluzione iniettabile
janssen-cilag ag - teclistamabum - soluzione iniettabile - teclistamabum 153 mg, natrii acetas trihydricus, acidum aceticum glaciale, saccharum, polysorbatum 20, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1.7 ml corresp. natrium 0.43 mg. - multipli myelom - biotechnologika